➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Colorcon
Moodys
Medtronic
Dow
AstraZeneca

Last Updated: June 1, 2020

DrugPatentWatch Database Preview

Litigation Details for Aventis Pharmaceuticals Inc. v. Barr Laboratories Inc. (D. Del. 2006)


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Aventis Pharmaceuticals Inc. v. Barr Laboratories Inc. (D. Del. 2006)

Docket   Start Trial Date Filed 2006-05-02
Court District Court, D. Delaware Date Terminated 2009-01-07
Cause 28:1338 Patent Infringement Assigned To Gregory Moneta Sleet
Jury Demand None Referred To
Parties AVENTIS PHARMACEUTICALS INC.; BARR LABORATORIES INC.; SANOFI-AVENTIS US LLC
Patents 10,086,011; 10,124,014; 10,184,001; 3,897,779; 4,018,895; 4,335,121; 4,405,598; 4,587,258; 4,590,213; 4,767,612; 4,782,047; 4,837,223; 4,843,086; 4,886,812; 4,933,168; 4,943,639; 4,971,998; 4,983,595; 5,053,407; 5,061,722; 5,216,007; 5,439,670; 5,461,081; 5,540,930; 5,543,434; 5,976,573; 6,121,021; 6,143,329; 6,673,337; 7,012,066; 7,449,012; 9,194,011
Attorneys John G. Day; Josy W. Ingersoll; Karen Elizabeth Keller; Karen L. Pascale; Steven J. Balick; Tiffany Geyer Lydon
Firms Shaw Keller LLP; Young, Conaway, Stargatt & Taylor LLP
Link to Docket External link to docket
Biologic Drugs cited in Aventis Pharmaceuticals Inc. v. Barr Laboratories Inc.

Details for Aventis Pharmaceuticals Inc. v. Barr Laboratories Inc. (D. Del. 2006)

Date Filed Document No. Description Snippet Link To Document
2006-05-02 1 Complaint cavities, U.S. Pat. Nos. 3,780, 176; 3,809,294; 3,897,779; 4,405,598; 4,250,163; 4,294, 829; 4,304,765; ….... 154/39 3,809,294 5/1974 Torgeson 222/182 3,897,779 8/1975 Hansen .......... 128/203.15 4,226,848 …cavities, U.S. Pat. Nos 3,780,176; 3,809,294; 3,897,779; 4,405,598; 4,250,163; 4,294,829; 4,304,765; 4,407,792…and 1400(b). The Patents 8. United States Patent No. 5,976,573 (“the ‘57 3 patent”) duly and legally…Action 4. This is an action for patent infringement arising under the patent laws of the United States, Title External link to document
2006-05-31 10 Opening Brief in Support __._S_., Patent Nos. 4.837.223 (the “ "223 natent”1 and 4.943.639 (the “ '639 patent") for…has infringed two patents Aventis owns, U.S. Patent Nos. 5,976,573 (“the ‘573 patent”) and 6,143,329 (…claimed in a patent or the use of which is claimed in a patent before the expiration of such patent 35 U.S.C…inventors 3 patent case that we have. patent cases by definition are 4 on one of the patents at the time… the Patent Act permits an award of enhanced damages for willful infringement in ordinary patent infringement External link to document
2006-06-09 11 Answer to Counterclaim Sanofi-Aventis listed U.S. Patent Nos. 5,976,573 ("the '573 patent") and 6,143,329 ("…and '329 patents, Barr's ANDA includes paragraph IV certifications to those patents. ANSWER… include, among other things, the number of any patent that claims the "drug" or a "method… the NDA was submitted and for which a claim of patent infringement could reasonably be asserted against…6. Upon approval of the NDA, FDA publishes patent information for the approved drug in the " External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Mallinckrodt
Colorcon
Baxter
Moodys
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.